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Abstract
Familial hypercholesterolemia (FH) is a serious inherited disorder, which greatly increases individuals’ risk of cardiovascular
disease (CVD) in adult life. However, medical treatment and lifestyle adjustments can fully restore life expectancy. Whilst
European guidance advises that where there is a known family mutation genetic testing is undertaken in early childhood, the
majority of the at-risk population remain untested and undiagnosed. To date, only a small number of studies have explored
parents’ and children’s experiences of testing and treatment for FH, and little is known about interactions between health
professionals, parents, and children in clinic settings. In this study, in-depth interviews were undertaken with parents who had
attended a genetics and/or lipid clinic for FH with their children (n = 17). A thematic analysis revealed four main themes:
undertaking early prevention, postponing treatment, parental concerns, and the importance of the wider family context. The
majority of parents supported genetic testing for FH in childhood. However, although some were very supportive of following
early treatment recommendations, others expressed reluctance. Importantly, some parents were concerned that inappropriate
information had been shared with their children and wished that more time had been given to discuss how, when, and what to tell
in advance. Future research is needed to explore the long-term outcomes for children who undertake genetic testing and early
treatment for FH and to trial interventions to improve the engagement, follow-up, and support of children who are at risk, or
diagnosed, with this disorder.
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Introduction
Predictive genetic medicine and personalised genomics are
heralded as having great potential to improve public health
and clinical care, with pre-symptomatic genetic testing expect-
ed to become increasingly available for a wider range of com-
mon and/or complex disorders (Burton 2011). This form of
testing determines whether an individual has inherited a gene,
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or set of genes, which causes—or increases the risk of—a
disease, long before its onset. In choosing to pursue pre-
symptomatic genetic testing, patients can use the findings to
inform decisions about any early treatment and make be-
havioural or lifestyle changes to help reduce their risk
of developing the disease in later life (Evans et al. 2001;
Skirton et al. 2013; Godino et al. 2016). However, studies
have shown that there is considerable variation in the uptake
of pre-symptomatic genetic testing by at-risk individuals
across a range of conditions, even when treatment and/
or preventative options are available (Forrest et al. 2012;
Nordestgaard et al. 2013; Delikurt et al. 2014).
In this paper, we describe the views and experiences of
parents with familial hypercholesterolemia (FH); a serious
inherited disorder associated with premature morbidity
and death from heart disease. Pre-symptomatic genetic
testing is available for individuals at risk of FH, and
treatment with medication and lifestyle adjustments has
been shown to fully restore life expectancy (Nordestgaard et
al. 2013). However, as many as 85% of cases are undiag-
nosed—and untreated—in the majority of European coun-
tries, (Neil et al. 2000; Marks et al. 2004; Nordestgaard et al.
2013), with studies suggesting that there are multiple barriers
to cascade screening and treatment of at-risk relatives
(Muir et al. 2011; Hardcastle et al. 2015).
FH is an autosomal dominant inherited condition leading to
high cholesterol in affected families, where all first degree
relatives have a 50% risk of inheriting the condition. It is a
Bmajor cause of premature macrovascular arteriosclerotic dis-
ease and cardiac death^ with 50% of males developing coro-
nary disease by the age of 50 and a 50%mortality by age 60 if
untreated (Finnie et al. 2012: 243). Women have a similar
spectrum of disease developing 10 years later (Finnie 2010).
The commonest cause is a gene change in the LDL (low-
density lipoprotein) receptor located on chromosome 19
(Finnie et al. 2012).
FH is considered common, because it is estimated to affect
approximately 1 in 500 people in the general population, al-
though recent studies suggest the prevalence is higher (Brice et
al. 2013). At the very least, there are between 1.8 and 4.5 million
people affected in Europe, with more than 120,000 cases in the
UK and over 11,000 in Scotland (Finnie 2010; Brice et al. 2013).
In order to prevent such high rates of disease, a system of
cascade screening for heterozygous FH—using genetic testing
and family contact methods—was introduced in Scotland in
2008 following UK NICE Guidance (National Institute for
Clinical Excellence 2008; Finnie 2010). This system uses in-
dex patients who have been diagnosed with FH through ge-
netic testing to alert at risk relatives, in the hope that they too
will seek testing and initiate treatment if diagnosed (Finnie
2010; Finnie et al. 2012). The advantage of genetic testing is
that it provides index cases with a definitive diagnosis and the
aberrant gene can be looked for in relatives, whereas the
results of lipid testing may be ambiguous (Hallowell et al.
2016; Personal communication with Dr. Finnie, April 2018).
Family contact methods are a more indirect form of screen-
ing, which relies upon family communication, in contrast to
direct cascading where a clinic contacts at risk relatives by
phone or letter (Hallowell et al. 2011).When using the indirect
approach, index patients are asked to pass on personalised
clinic letters/information to at risk relatives who have been
identified through discussion between a patient and genetic
counsellor about family tracing and may benefit from screen-
ing (Hallowell et al. 2011). Whilst both methods raise a num-
ber of ethical dilemmas, it is acknowledged that the indirect
form may result in less uptake and unknowing relatives
(Hakimian 2000; Hallowell et al. 2011).
Familial hypercholesterolemia in children
Studies have shown that initiating statin treatment from child-
hood can significantly reduce the risk of CVD in adult life
(Nordestgaard et al. 2013; Luirink et al. 2015) and that statin
use is safe in children (Humphries et al. 2018). As a result,
recent European guidance advises that where there is a known
family mutation, genetic testing is carried out in early child-
hood (Nordestgaard et al. 2013). If a positive result is found,
children are encouraged to adopt a healthy lifestyle at as early
an age as possible; with statin treatment considered by age 10
(Nordestgaard et al. 2013). Thus, whilst genetic testing in
childhood for adult-onset conditions is usually not advised
(Lucassen et al. 2010), it is considered permissible—even
encouraged—in FH where there is Bsimple^ and effective
preventative treatment (Nordestgaard et al. 2013; Luirink et
al. 2015). This discourse is particularly apparent in the
medical literature on FH (Wiegman et al. 2015), as well
as in patient organisations where there have been Bcalls
to action^ to Bbring greater attention to this potentially deadly,
but (with proper diagnosis) eminently treatable, condition^
(Knowles et al. 2014).
A small body of work has explored parents’ and children’s
views about FH, suggesting that there is strong support from
families to undertake genetic testing in at risk children, with
little evidence of any psychosocial problems (Tonstadt et al.
1995; Tonstad 1996; Umans-Eckenhausen 2002; Jongh et al.
2003). Furthermore, there are limited reports of parents’ de-
clining testing uptake (Weiner 2011), supporting wider studies
of favourable parental attitudes towards predictive/
presymptomatic genetic testing in children where treatment
options are available (Michie et al. 2001). However, one paper
does report parental concerns that children may worry about,
or resist, their diagnosis (Weiner and Durrington 2008).
In Scotland, the uptake of genetic testing for FH has im-
proved since the introduction of cascade screening (HEART-
UK 2013). Nevertheless, the majority of the at-risk population
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remains untested and undiagnosed, with particular concerns
about low uptake rates for children and young people
(Familial Hypercholesterolemia Governance Group 2010;
HEART-UK 2013). A similar picture has been observed across
the UK, where recent studies indicate that cascade screening is
underused in children of women with FH (Benson et al. 2016).
Whilst the medical literature now strongly encourages early
detection and treatment of FH from childhood, only a small
number of studies have explored parents’ and children’s in
depth views, and little is known about interactions between
health professionals, parents, and their children in clinic set-
tings. The aim of this study was to explore parents’ views and
experiences of genetic testing and early treatment of children
with FH in Scotland (UK), experiences of their children’s care
pathway and to identify any barriers or facilitators in testing
and treatment uptake. In-depth interviews with children and
young people were also conducted during the fieldwork and
will be reported in a separate paper.
Methods
The data for this paper were generated from a CSO (Chief
Scientist Office, Scotland) study, which aimed to explore the
Bsharing of information between parents and children about
genetic risk,^ using FH and Huntington’s disease as two con-
trasting exemplars. The overall study design included four
linked phases of research: interviews with genetics profes-
sionals; clinic observations; prospective and retrospective in-
terviews with parents and children; and collaborations with
patient groups to develop information for children and young
people. This paper reports the findings of interviews with
parents who have FH.
The study was approved by the North of Scotland Research
Ethics Service (REC Ref: 11/AL/0146).
Inclusion and exclusion criteria
Participants were eligible for the study if they had attended a
clinic for FH where cascade testing and/or disclosure to chil-
dren was raised by the genetics or lipid professional, and they
were able to give signed written informed consent.
The clinicians did not invite any participant considered too
vulnerable to participate, e.g. those who had had a recent
bereavement. Parents whom the clinicians viewed as unable
to give informed consent were not included.
Recruitment and sampling
In the FH group, parents and children were recruited through
clinical genetic services and lipid clinics across Scotland be-
tween August 2011 and October 2014 by their health profes-
sional (a lipid consultant, genetic counsellor or clinical
geneticist). The majority of participants were referred for ge-
netic counselling and had attended a lipid clinic. Eleven were
recruited by a clinical geneticist, three through a genetic coun-
sellor and three through a lipid doctor. Initially, we planned to
recruit from one site (Grampian), but by early 2012, we dis-
covered that only six children had been tested and found to
have a gene mutation for FH in that site. At this point, we
broadened the recruitment strategy to include two additional
sites (Lothian and Greater Glasgow and Clyde).
Potential participants were sent an invitation letter with an
information leaflet and a reply slip asking them to contact the
researcher if they wanted to participate. All participants had the
opportunity to ask questions about the study beforehand and gave
written consent. Purposive samplingwas used to recruit as diverse
a range of participants as possible (Clarke and Braun 2013).
The participants
In total, 17 interviews were undertaken with parents, 13 had a
positive mutation result from DNA testing and a diagnosis of
FH, and four were the spouse of a patient with FH. Thus, all
parents, apart from four spouses, were mutation carriers and
had been interviewed after genetic testing. Three participants
had experienced symptoms such as angina or had CVD. All
participants had at least one child with an FH mutation. All
participants were married, except one who was widowed. All
described their ethnicity as BWhite.^ See Table 1 for
demographic information.












Post-secondary qualifications 12 70.6




One child, with FH mutation 6 35.3
Two children, one with FH mutation 4 23.5
Two children, both with FH mutation 5 29.4
Three children, one with FH mutation 2 11.8
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Data collection and analysis
Semi-structured interviews were conducted (by KFK) with
participants and lasted between 30 and 90 min. The majority
of interviews took place in participants’ homes or a hospital
clinic; two were by phone. All phone and in-person interviews
were audio-taped with consent and fully transcribed. Promises
of anonymity and confidentiality were given. The interviews
focussed on: family history of FH, reasons for seeking
childhood testing, parents’ experiences of the testing
process, views of testing and treatment in childhood,
the impact of any result, and any gaps in information
or support. Clinic observations were also undertaken to
enable the researcher to learn more about patient care
for FH.
The analysis was conducted in two main phases. An
initial thematic analysis was undertaken using a system
of open coding, the constant comparison method, and a
search for negative cases (Strauss and Corbin 1990;
Guest et al. 2011). KFK identified themes and catego-
ries by reading and re-reading transcripts. Different seg-
ments of the data were then grouped together into sep-
arate categories, allowing reflection on the major themes
and any relationships among them. The thematic analy-
sis was ongoing throughout the fieldwork until a point
of data saturation was reached about the main themes
(Strauss and Corbin 1990). In the later phase of analy-
sis, the findings were interpreted with reference to
existing psychological and social theory on families af-
fected by inherited conditions, where issues related to
engagement with genetic risk (McAllister 2003; Frich et al.
2007b), discourses of genetic risk and responsibility
(Hallowell 1999), patient (dis)empowerment (McAllister et
al. 2011), illness experiences (Frich et al. 2007a; Mackie et
al. 2015), and personal theories of inheritance (Wilson et al.
2004; Frich 2006) were anticipated to arise. We also anticipat-
ed that family communication about genetics would influence
parental attitudes and behaviour in this area (Forrest et al.
2003; Wilson et al. 2004; van den Nieuwenhoff et al. 2007).
Thus, whilst phase one aimed to generate inductive themes
from participants’ accounts, phase two interpreted these ac-
counts within a broader theoretical framework.
Results
We identified four main themes from parents’ interviews
about their experiences of genetic testing and treatment for
FH in their children. These were the following: (1) undertak-
ing early prevention; (2) postponing treatment; (3) parental
concerns; and (4) the wider family/social context. Within each
main theme, we identified several subthemes (see Table 2).
Undertaking early prevention
Early prevention was a prominent theme, with parents citing their
support for statin treatment and lifestyle adjustments in childhood.
Parents described several key factors, which influenced their de-
cision, such as witnessing serious FH events in other relatives,
experiencing their own symptoms, knowing there was a family
history of heart disease from an early age, and having trust in their
health professional. The need to tell children about their risk, or
diagnosis of FH, was threaded throughout these accounts.
Protecting children’s future health
Just over half of participants supported the genetic testing of
children for FH and instigating statin treatment from an early
age, asserting that preventative medication would protect their
child’s future health. A consistent theme was that participants
had witnessed serious FH related events in other close rela-
tives or had experienced symptoms themselves. These expe-
riences created a strong desire to Blook after^ their children’s
future health, with statin treatment viewed as a key mecha-
nism of prevention. For example:
We want to help him, give him as good a shot as he can
get…When you look at what happened to my dad - at 47
he had a heart attack… You just think it’s your son! You
want to wrap them up in cotton wool… [So] we’ve de-
cided to give him statins until he’s 16…We’ve covered
him until he’s old enough to decide for himself. (FH7)
If that’s what it takes then they’ll get them… I mean my
daughter lost her sibling, you take note of that … and
look after your family. It was so obvious that it was
coming down the line. (FH1)
Table 2 Main themes and
subthemes Themes Subthemes
Undertaking early prevention Protecting children’s future health; awareness of heart disease in family
from childhood; trust in health professionals; telling children about FH
Postponing treatment in children Parental responsibility to assess risks versus benefits; differences in medical
advice; gender; low estimation of risk
Parental concerns Age inappropriate communication with children in clinic; giving blood in
childhood; statin treatment in children; normalisation over medicalisation
The wider family context Parenting threatened; making family comparisons.
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Awareness of heart disease in family from childhood
Several parents reported being aware of a family history of
heart disease during their own childhood and that they had
always felt at high risk themselves. As a consequence, they
had taken preventative measures throughout their lives and
were supportive of genetic testing and treatment for FH in
their children. However, whilst one participant grew up know-
ing about FH specifically—and had taken statins since child-
hood, the other had had little knowledge of the condition
itself, or the prescription of statin treatment for FH, until re-
cently. Although he had followed a Bstrict^ regime of diet and
exercise, describing a Bvery clean^ lifestyle, he still developed
angina in his 30s and asserted that recent developments in
research would help his children:
It’s more than 20 years ago since my father died. So it
was in my mind all the time that there is a sign, espe-
cially with my uncle dying too… In my case it seemed
to be learning things a little bit too late [about FH] be-
cause I didn’t take any statin or anything. It became clear
2–3 years ago, even though I live a healthy lifestyle, the
faulty gene is the root of my problem and if I don’t have
an operation or do something I will probably die …. I
would have been taking statins before but because of
what I don’t know [I didn’t]… That's why research
and everything it would help my children. (FH10)
In contrast, this mother described how:
I’ve known about FH since I was a kid and have always
been on some kind of medication … My dad’s now in
his 70s … It’s not something I feel particularly threat-
ened about having… People on statins live a long long
time… So I was absolutely keen to get my son tested.
(FH16)
Trust in health professionals
Participants also reported having a sense of trust in their doc-
tor, or genetic counsellor, particularly if they had a long-term
consistent relationship with the same health professional and
their cholesterol levels had been lowered following advice to
take statins. If parents trusted their health professional then
they were more likely to be receptive about advice to seek
genetic testing and statin treatment in their children. For
example:
I think with Dr X, because we’ve been working together
for that long, and I’ve seen my cholesterol come down, I
would totally trust his judgment on what's the right
thing. Whatever he's saying I would accept really.
(FH18)
Telling children about FH
In this theme, parents also supported telling children about
FH, with some encouraging openness from a young age,
asserting that this would help children adjust to any diet, med-
ication, and lifestyle changes.
It’s better to know now from an early age and to
adjust to that straightaway … If you can get them
when they’re young and impressionable that becomes
a habit. (FH23)
However, others indicated that they had taken, or would take,
a more incremental approach to telling their children, which
was dependent on their child’s age, medical advice, and
whether there was any action that could be taken or not. For
example:
I wouldn’t want him to find out too young. I’ll
probably wait until he’s a bit more mature then
sit down and explain it to him. He could get wor-
ried. I don’t think it’s anything to be worried
about, but you never know how he’ll feel and how he’ll
react to it. (FH7)
Obviously when children are quite young you can’t give
them information that they can’t do anything with, other
than worry. I did try and do it… according to their age,
and what needed to be done as I was told at the time…
and the doctor said there’s no point doing anything until
after puberty. (FH5)
In this case, a participant had sought advice about her
daughter’s risk of FH from her GP, but was advised
that there wasn’t anything that could be Bdone^ until
after she finished puberty. Thus, whilst she told her
daughter about her risk of FH when she was in her
early teens, they postponed Bdoing anything^ until
adul thood, in t imat ing tha t th is inc luded fu l ly
Beducating^ her about the family history. As a conse-
quence, she reflected that:
My daughter can’t understand why I didn’t give her
more details when she was younger… but things have
come on so quickly. (FH5)
In other families, participants reported a much more limited
approach to disclosure, deferring responsibility for educating
their children about FH to a health professional:
I’ve never really spoken with her myself about
FH, but the genetic counsellor told her all about
it. We actually don’t talk about it, do you know
what I mean? (FH 28)
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Some participants also asserted that they used health
professionals in a supporting role to inform their children
about FH:
It’s reinforcement for the children, it was better coming
from professionals than from us – saying this is what
you should be eating. (FH3)
Postponing treatment in children
In this theme, less prominence was given to medical
authority, with parents asserting that they had a respon-
sibility to assess the risks versus benefits of early treat-
ment themselves. A few participants had received dif-
fering advice from health professionals about the need
to initiate early statin treatment in children. We also
found participants who felt they had a low risk of developing
CVD, citing gender as a protective factor.
Parental responsibility to assess risks versus benefits
Several participants questioned the benefits of initiating statin
treatment in children. Whilst these parents did express trust in
their health professional, it was countered with a sense of
parental responsibility to question the advice they were given,
particularly if they had previous experience of poor health care
or lack of follow up. Parents described taking Bownership^ of
their children’s healthcare by seeking further information
about FH and probing their health professional about risks
versus benefits.
Although I trust the doctors I know that having seen the
treatment my mum got, I'm not saying that she bad
treatment… but there was not much in the way of fol-
low up. So you can’t always assume that it’s going to
come to you and somebody is going to come and give
you an answer … I think you've got to try and think
about it yourself as well, and take ownership of it, not
see it as somebody else’s responsibility … So I might
push it in terms of trying to find out what the benefits
are. (FH23)
Differences in medical advice
Participants also reported receiving conflicting advice from
different healthcare professionals (e.g. their GP, paediatrician,
lipid consultant, or genetic counsellor) about the importance
of genetic testing and statin treatment in children for FH.
Whilst a sense of Btrust^ in a medical doctor was again evi-
dent, participants were uncertain about the benefits of early
statin treatment, questioning why it should be initiated so
young, particularly if other health professionals were confi-
dent about delaying. For example:
I think we had two slightly different views, the genetic
counsellor was more relaxed about it, the medical doctor
less so. And it’s hard then to know which to go with…
At the end of the day I think I trust the doctors… But I
might ask questions to have a better understanding of
the advice they’re giving. So for my daughter, I would
ideally like to postpone her taking statins for as long as
possible. (FH23)
Others highlighted that medical knowledge and treatment ad-
vice about FH has changed over time, which could also rein-
force uncertainty about early statin treatment being the Bright
solution^ for children.
We were told there was no point in testing children until
they were teenagers and it wasn’t such a problem for
females, it was a male thing. But I think we’ve all come
past that now. (FH2)
As to the ideal treatment … I don’t think the medical
profession could guarantee 100% that they have the
right solution, the right solution changes on what decade
you’re in I think. (FH27)
Gender
A few participants asserted that gender could be a factor in
postponing statin treatment in female children. Currently, med-
ical advice is to stop taking statins in pregnancy and when
breastfeeding; given this advice, it was envisaged that teenage
girls and young adult women may choose to postpone any
statin treatment until their 20s—or even their 30s. For example,
I think any female receiving that information is going to
question whether she needs to take the drug until
after … she’s had her family. (FH14)
The same participant also admitted that she had chosen to
delay genetic testing and statin treatment because she was
premenopausal, asserting that this gave her some Bprotection^
against heart disease.
I assumed that… because of my age… I was protected.
(FH14)
Low estimation of risk in children
In some accounts, it was clear that FH was not viewed as an
overly threatening condition by a parent nor to the health of
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their children. In these circumstances, there was no sense of
urgency about children starting statin treatment, which could
extend to adult children too, particularly if a parent had not
experienced any symptoms or anxiety about FH themselves.
I mean this is high cholesterol, I know it has its prob-
lems, but it’s not a scary one. I haven’t got any fear that
my heart is about to stop. (FH14)
This parent was unconcerned when her adult daughter also
chose to delay treatment, commenting that:
Her cholesterol is six and she just says ‘look I’ll deal
with it!’ [Laughter]. So I presume she will one day.
(FH14)
Parental concerns
Throughout these accounts, parents voiced a number of
concerns, primarily about when to initiate treatment for
FH in one’s children and how best to manage their
clinical care. Two further concerns related to parents’
experiences of inappropriate communication with their
children in clinics and a desire to retain normality over
medicalisation, with some highlighting the dilemmas of
genetic testing in childhood.
Inappropriate communication with children in clinic
Several participants reported concerns about the information
that professionals had given to their children at different ages/
developmental stages during consultations about FH, for ex-
ample, contraceptive advice given to a 9 year old by a doctor,
which was felt to be highly inappropriate.
The doctor at the hospital went into far too much depth.
He was talking about contraception and things. I’m sit-
ting going she’s only nine! She actually doesn’t know
what sex is. A lot of it just went totally over her head.
(FH28)
In contrast, this mother and her daughter had also been to a
consultation with a genetic counsellor who:
Just totally talked to her, more than talked to me. Totally
down to her level, explained it real good, didn’t explain
anything long. You can give toomuch information that’s
not needed. (FH28)
One couple also reported concerns about how informa-
tion about FH had been conveyed to their child during
a conversation at a family appointment when they had
raised questions about the benefits of early treatment,
describing a lack of parental consultation or involve-
ment in this process.
Father: The doctor was clearly quite anxious that he laid
the facts very bare before us, I think to let us understand
the importance of accepting the drugs … And perhaps
there was more attention paid to that aspect of it than
there was to the effects information like that could have
on the mind of a 13 year old. He put it very very starkly
… I’m not saying that that information should not have
been shared with us, but it should probably have been
shared with us, privately, rather than with all three of us,
to allow us to judge whether or not it was something we
would want shared with our daughter at that stage.
(FH29)
Mother: So I think for me a separate appointment would
have been helpful for us to discuss our concerns, and
then have had the joint appointment with our daughter
as a follow-up … We’re saying the lipid specialist
should have better training in communicating with chil-
dren. That was clearly missing.
There was also concern from parents about how medical pro-
fessionals would frame future conversations with their chil-
dren, particularly around healthy eating, with some mothers
asserting anxiety about the possibility of eating disorders in
teenage girls, and how to balance this with information about
FH.
I’m very conscious of wanting my children to have a
very healthy relaxed relationship with food. I don’t want
her to have that ‘fat is bad’ message… I don’t want that
from a consultant… Screwing with a teenagers relation-
ship with food is a volatile playground… [You need to]
know what age person you’re talking to and what the
other vulnerabilities are. (FH26)
Giving blood in childhood
Having to give blood in childhood was also raised as an im-
portant concern by parents as it was usually the first time that
children had experienced venepuncture. Whilst it was intimat-
ed that this may not be a huge concern for adults, there was an
appeal to view this from a child’s perspective. Thus, according
to one father:
The thing that has absolutely traumatized her is going to
give blood… She just reacted really badly to it. (FH18)
Unfortunately, the experience of giving blood was very
distressing for this participant’s daughter, which he felt had
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been intensified by attending an adult lipid clinic with no
specific facilities or advice for children, e.g. to apply anaes-
thetic cream beforehand.
Strong concerns about statin treatment in children
Three parents reported having strong concerns about statin
treatment in children, not only because of their long-term
safety but also potential side effects. They had all sought fur-
ther information from the medical literature—and from other
patients—and concluded that the Bevidence base^ was equiv-
ocal; one queried whether statins were in fact Bdealing with
the right problem.^ For example:
It is a recent drug, and you don’t know what the long
term effect could be. And I’ve spoken to somany people
that have said they have this muscle ache… So how’s
my child going to know when to say ‘I don’t actually
feel quite right mummy?’ So I wouldn’t be keen to put a
child on a tablet, especially if he’s fit and healthy. (FH8)
I have concerns about what it does and doesn’t mean
and if statins are the right approach when it comes to my
daughter … It’s one thing when someone of 50 or 60
goes on to it, we’ve got a lot of experience with people
at that age. But the idea of putting something into some-
body who is not yet fully grown, that we don’t even
really know for sure is dealing with the right problem
freaks me out. (FH26)
These participants also reported a lack of trust in the medical
profession, citing historical examples of medical mistakes,
which have resulted in serious harm to children.
You don’t ever like the idea of your child being any sort
of a guinea pig, even if it's done … with the best of
intentions … I just think Oh God! … My husband is
from the Thalidomide era you know! (FH26)
Normalisation versus medicalisation
Whilst the primary concern of these parents was to avoid any
long-term harms from statin treatment in childhood, they also
wanted to protect the current health and wellbeing of their
children, indicating a desire to maintain normality and protect
Bchildhood^ itself from medicalisation. For example:
The reality of it when it sinks in that your daughter has a
genetic condition, it’s hard on a number of levels… It’s
hard because you don’t want that for any of them… As
a parent you want your child to live their childhood
carefree, happy, skipping through the wind! You don’t
want them burdened with this. (FH26)
Protecting children from medical intervention could also ex-
tend to notions of heredity and genetic risk. For example, in a
joint interview with a mother and son (aged eight), his mother
spoke in whispers when using words, such as Bhereditary^ or
Bgenetic.^
In some cases, parents made the decision that their children
were Bfar too young^ to begin lifelong treatment on statins and
chose to disengage from the paediatric and genetics service,
asserting that they would return when their children were old
enough Bto decide for themselves.^ One parent had not
attended any further appointments with her subsequent chil-
dren, commenting that:
Part of me thinks I should never have got involved with
this. (FH8)
Three parents described their feelings about the dilemmas of
genetic testing and the consequences this may have for their
children, acknowledging that whilst there may well be long
term health benefits, there can also be negative implications:
I feel a bit damned if you do, damned if you don’t. It’s
the challenge with genetic testing – on the one hand its
clearly better to know, on the other it does bring its own
set of worries. She’s not going to have as many options
as someone without those concerns would have. (FH26)
Wider family context
Another key theme in parental accounts was the importance of
the wider family context in relation to views about genetic
testing and treatment of children for FH. Testing for FH may
be particularly sensitive if parenting itself had been previously
threatened, or was felt to be under threat. Participants also
compared family members to each other to assess their own
personal or child’s risk, with some extending this beyond FH.
Parenting threatened
In a few cases, parents’ accounts revealed sensitive circum-
stances where they had had to protect their children and/or
where parenting itself had recently been threatened, e.g. pa-
rental divorce or a parent’s ill-health, which appeared to
heighten their anxiety about their children’s welfare and feel-
ings of protectiveness about their children’s health. For exam-
ple, one mother described the difficult time she had during her
pregnancy:
I ended up spending most of the pregnancy absolutely
terrified that I was doing something to her… I had to go
through drugs [in my pregnancy] that quote unquote
they ‘did not know to be unsafe’. That’s not the same
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thing as safe!… I don’t make any connection between
that and the FH, but it’s like … oh look, we’ve finally
got this baby! (FH26)
Throughout her interview, this mother was clearly anxious
about the potential of FH treatment Bdoing something^ harm-
ful to her child.
We also observed a parent being offered a referral to
Bpsychology^ to discuss the concerns she had about testing
and statin treatment in her children, and to help with her
Bdecision making,^ from which she left visibly upset
(Fieldnotes from clinic observation, 2013). However, during
her study interview several months earlier she had already
asserted her view that:
While they are young and they are little, for me, it’s a no.
And if that decision were taken away from me then I
would be quite upset about it. (FH8)
Making family comparisons
Similar to other participants, one mother compared her-
self with her siblings who had high cholesterol—
assessing that their risk of developing heart disease
was far higher than her own because of lifestyle factors
such as smoking, excessive alcohol intake and poor diet.
As a result she deduced that her risk of heart disease—and her
children’s—was lower than her relatives, insinuating that luck
and chance also play a role:
My brother just had a heart attack … but he’s a heavy
smoker, doesn’t eat well and is overweight. I mean I’m
not a particularly great eater, but I don’t smoke and I
don’t drink excessively, and then you know there are
people who are perfectly healthy [and have a heart
attack]! (FH8)
Parents also described making health comparisons be-
tween their children, as well as examples of children
comparing their health with that of siblings, leading
one mother to assert:
Strangely she’s the one that’s inherited all the ailments –
she’s the one that has to wear glasses, she’s the one that
got asthma and is also the one that’s got high cholesterol
… In her younger days she asked why am I the one that
has all the problems? (FH2)
A few participants also described other serious illnesses they
had witnessed within their family, for example, breast or ovar-
ian cancer, acknowledging that they would be supportive of
pre-symptomatic genetic testing for other conditions if it was
available for their children.
What I would really like to say to them is what else can
you test her for? Let’s test her for the genes that predict
anything else. (FH27)
Discussion
This article is the first to explore UK parents’ in depth views
and experiences of genetic testing and treatment for FH in
children. A qualitative analysis was undertaken, which iden-
tified four main themes from parents’ accounts: (1) undertak-
ing early prevention; (2) postponing treatment; (3) parental
concerns; and (4) the wider family context.
A key finding was that just over half of parents (n = 9) were
supportive of genetic testing for FH in children and early
treatment with statins. This is similar to previous studies of
parental attitudes towards genetic testing and treatment of FH
in children, which found that the majority of parents had a
positive attitude towards screening children for FH (Tonstadt
et al. 1995; Tonstad 1996; Umans-Eckenhausen 2002). Also
similar to previous studies, we found that many participants
had a strong sense of illness vulnerability from experiencing
personal symptoms themselves or witnessing serious illness
events in close family members (Frich 2006; Jenkins et al.
2012), creating a desire to protect their children’s health and
avoid repeating history. Our findings support studies of genet-
ic responsibility where parents feel they are Bdoing the right
thing^ by seeking genetic testing and undertaking risk man-
agement strategies, particularly if they are a new parent
(Hallowell 1999; Frich 2006). Indeed, one of themain benefits
of DNA testing for FH maybe to provide information for
future generations (Hallowell et al. 2016).
We also found participants who had grown up with a well
parent whom they had witnessed undertaking long-term pre-
ventative measures and was viewed as a role model for FH
related health behaviour, which was now encouraged in their
own children. Our findings support other work, which sug-
gests that these participants were Bintensely engaged^ with
their risk (McAllister 2003) and felt a shared sense of Bfamily
identity^ (Jenkins et al. 2012), highlighting the importance of
prior family experiences (Mackie et al. 2015). However, FH
was not viewed as a significant burden, but more of a lifestyle
adjustment, involving a healthy diet, exercise, and statin treat-
ment from an early age. This could be viewed as an example
of preventative genetic medicine occurring Bdown the line^
through several generations, similar to clinic observations in
other serious inherited conditions. For example, heredi-
tary breast/ovarian cancer where several generations may
choose to undertake a preventative mastectomy (personal
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communication with ZM). Having a strong sense of trust in
the medical profession as a whole and a long-term consistent
relationship with an FH health professional was also an im-
portant factor in testing uptake and acceptance of treatment in
participants’ children.
In contrast to other studies, an important finding was that a
subgroup of parents were more reluctant about early statin
treatment in their children, preferring to delay this for as long
as possible. Participants with poorer experiences of healthcare
and those who were active information seekers tended to chal-
lenge professional advice, asserting that it was a parental re-
sponsibility to assess any risks versus benefits of early treat-
ment with medication. Our findings also draw attention to
participants who had received conflicting advice from differ-
ent healthcare professionals about the importance of early
statin treatment in children, raising dilemmas for parents about
whose advice to follow. This supports other studies, which
suggest that uptake rates for FH differ according to the
healthcare setting patients attend, e.g. general practice versus
lipid clinics (Jenkins et al. 2012). Given that there are
differences in professional views about the ethics and
implementation of preventative genetics in children, in-
cluding FH, this may influence the advice which parents re-
ceive (Chapple et al. 1996; Will et al. 2010).
Another important finding was that participants with a less
visible family history of FH, who had no contact with affected or
at-risk relatives, or forwhomFHwas a recent diagnosis, had little
sense of an FH Bfamily^ or Bgenetic^ identity, and perceived the
condition as less threatening (Frich 2006;Weiner andDurrington
2008; Claassen et al. 2010; Jenkins et al. 2012). As a result, there
was less incentive to seek genetic testing in children, or comply
with early treatment advice, with a similar pattern of procrastina-
tion observed in participants’ adult children. Gender was also
cited as important in young women’s decisions to delay or use
treatment intermittently as women may not want to initiate statin
treatment until after they have completed their family, and being
premenopausal was viewed as a Bprotective^ factor against risk
of heart disease. Similar to previous studies, parents also drew on
more environmental models of the Bcoronary candidate^ and
notions of luck and chance, which lessened their personal sense
of vulnerability—and risk to children (Frich et al. 2007b;Weiner
2009). In addition, we observed parents who compared them-
selveswith other high risk familymembers, calculating their own
risk as lower (Frich 2006).
In contrast to previous studies, our findings draw attention to
a subgroup of parents who were particularly anxious about ini-
tiating early statin treatment in their children, questioning the
safety of using statins in children and the lack of long-term
empirical evidence about their efficacy. Parental reluctance, or
anxiety, about the use of statins in childhood exemplifies the
ambivalence, fear, and responsibility, which many parents
expressed about the management of their children’s health, par-
ticularly in relation to early treatment (von der Lippe et al.
2017). In addition, our study lends some support to previous
work in other adult-onset inherited conditions, which found that
parents may place a high value on maintaining Bnormality^
(Forrest Keenan et al. 2015) and protecting childhood from
potentially unnecessary medical intervention and surveillance.
Similar to other studies, our data also draws attention to the
importance of a parent’s psychosocial context, as genetic test-
ing in children may bring sensitive personal and family issues
to the surface, e.g. guilt and shame (Wilson et al. 2004; Frich
et al. 2007a), or even threaten parenting itself. Our findings
support the work of McAllister (2003:500) who suggests that
when participants experience engagement as Btoo painful,^
they may disengage, even if they were previously Bintensely
engaged^ with their risk. In these circumstances, we observed
that parents may disengage their children, or choose not to
refer any subsequent children. In addition, our findings draw
attention to parents who felt pressured to initiate early statin
treatment in their children, reinforced by very graphic infor-
mation, or even a psychology referral to Bhelp with decision-
making^ which may ultimately disempower, rather than em-
power, patients with inherited conditions (McAllister et al.
2011; Metcalfe et al. 2011). Similar to our previous work,
we observed that parents may also be Bcoming to terms^ with
their own, and/or their children’s diagnosis, and were either
Bnot ready^ to comply with treatment advice or used distanc-
ing as a coping strategy (Forrest et al. 2003; Frich 2006; van
den Nieuwenhoff et al. 2007). Taken together, these parental
concerns may go some way to explaining barriers to uptake
and initiation of early treatment. Our findings also raise ques-
tions about the long-term implications for children known to
have FH if parents choose to disengage them from FH ser-
vices, although the use of a more direct contact, or a mixed
approach, to cascade screening could help address this issue
(Newson and Humphries 2005; Hallowell et al. 2011).
Whilst disclosure to children about FH was not generally
portrayed as a burden by participants, our findings draw atten-
tion to the supportive role of health professionals in sharing
genetic risk information with children (Forrest et al. 2003;
Metcalfe et al. 2011). Similar to other studies, we found par-
ents who only Balerted^ children about their risk of FH, but
deferred responsibility for fully Beducating^ them to a health
professional (van den Nieuwenhoff et al. 2007), although dis-
closure could also be a more joint and shared process between
parents and health professionals (Cribb and Entwistle 2011).
Nevertheless, a new finding is that children and parents had
experienced Bunsanctioned^ disclosure, where health profes-
sionals had presented Bstark^ or inappropriate information,
with little or no clinical time given to seeking parental views
about the process of disclosure itself. Given the importance of
parental Breadiness,^ and the potential to disengage, this
seems an important but potentially neglected aspect of care
which is likely to influence a parent’s sense of empowerment
and engagement.
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Limitations of study
There are several limitations to our study. Firstly, it is a
UK study and the data may not apply to other popula-
tions, where there are different screening methods and
healthcare systems. A second limitation is the small
sample size, although we did broaden our recruitment
strategy to include different geographical locations, in-
creasing the diversity and range of experiences. A fur-
ther limitation is that we recruited more female than
male participants. Our findings may also be subject to
recruitment bias as patients who are more supportive of
testing and treatment in children may be more likely to
participate in research. Future studies would benefit
from recruiting more fathers, exploring the views of
children and young people, and those who have declined
testing.
Conclusion
This paper adds to a growing body of work about pre-
ventative genetics and the role of parents as gatekeepers
in childhood genetic testing for serious treatable
inherited conditions like FH. Whilst just over half of
parents supported genetic testing and early treatment
recommendations in children, others expressed several
concerns, particularly about the use of statins in child-
hood. Parental engagement was influenced by having a
strong sense of personal vulnerability, open styles of
family communication, and trust in the medical profes-
sion. Disengagement of children occurred when parent-
ing was threatened and patients felt disempowered. In
general, parents did not feel that disclosure to children
about FH was a burden. However, some were concerned
that inappropriate information had been shared with
their children and wished that separate time had been
given to discuss how, when, and what to tell them.
Future research is needed to explore the long-term out-
comes for children who undertake genetic testing and
early treatment for FH and to trial interventions to im-
prove the engagement, follow-up, and support of chil-
dren who are at risk, or diagnosed, with this disorder.
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